Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD)

Zagazig University

Status: Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Treatments: Device: abdominal U/S; Device: Fibroscan with Controlled Attenuated Parameter (CAP scan):

Study type: Observational

Funder types: Other

Identifiers

NCT06097039

Diagnosis of the NAFLD

Details and patient eligibility

About

The work investigate the role of fetuin-A in the diagnosis and assessment of the severity of non-alcoholic fatty liver disease (NAFLD).

Full description

The prevalence of nonalcoholic fatty liver disease (NAFLD), which has recently become one of the most prevalent chronic liver illnesses, is about 25% worldwide. NAFLD is a progressive liver disease that can cause fibrosis and ultimately cirrhosis, in contrast to simple hepatic steatosis, which is considered to be a benign condition. The sole way to diagnose NAFLD and stage liver fibrosis has historically been a liver biopsy. There are a number of issues with this method, though. A liver biopsy is a painful and invasive diagnostic procedure that carries a risk of consequences.

Fetuin-A, also called the 2-Heremans-Schmid glycoprotein, belongs to the fetuin group of serum-binding proteins and is largely produced by hepatocytes. It is a phosphorylated glycoprotein. Fetuin-A can cause insulin resistance in the target organs, including the liver and skeletal muscle, as it is an endogenous tyrosine kinase inhibitor. A strong correlation between the level of circulating fetuin-A and the onset and progression of NAFLD has been described by accumulating lines of evidence, but the findings have been contradictory.

The investigators want to find out how fetuin-A affects the diagnosis and evaluation of the severity of non-alcoholic fatty liver disease (NAFLD) and to reveal the relationship between fetuin-A and the NAFLD fibrosis score (NFS).

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients who were admitted to the university hospitals with inclusion criteria

Exclusion criteria

• Patients who are younger than 18 years old,
• Patients with a history of high alcohol consumption (more than 40 g/day for men and 20 g/day for women) over the previous five years,
• Patients who have concurrent hepatitis B and hepatitis C viral infections
• Patients with hepatobiliary malignancy, Wilson's disease, alpha-one antitrypsin deficiency, and autoimmune hepatitis,
• Pregnant women
• Patients who take steatogenic pharmaceuticals including amiodarone, valproic acid, antiretrovirals, methotrexate, and tetracyclines, or NAFLD treatments like vitamin E, metformin, and thiazolidinediones

Trial design

100 participants in 2 patient groups

NAFLD subjects group

Description:

The group including 50 cases with NAFLD, the diagnosis was based on abdominal U/S and Fibroscan with CAP with or without elevated liver enzymes

Treatment:

Device: Fibroscan with Controlled Attenuated Parameter (CAP scan):

Device: abdominal U/S

Healthy subjects group

Description:

The group including 50 healthy subjects as a control group with normal liver in transabdominal ultrasonography and normal liver enzymes

Treatment:

Device: Fibroscan with Controlled Attenuated Parameter (CAP scan):

Device: abdominal U/S